Video

Dr. Spratt on “substantial benefit” of Decipher test for patients with intermediate-risk prostate cancer

“It's the first time that any gene expression test has been analyzed in a randomized trial, even if it's post-hoc, in intermediate-risk patients,” says Daniel E. Spratt, MD.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Daniel E. Spratt, MD, discusses the background and findings of the study, “Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126,” which was shared during the 2022 ASCO Genitourinary Cancers Symposium. Spratt is a Vincent K. Smith professor and chair at Case Western Reserve University School of Medicine and chair of radiation oncology at University Hospitals Cleveland Medical Center in Cleveland, Ohio.

      © 2025 MJH Life Sciences

      All rights reserved.